# Oculgen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oculgen

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.oculgen.com
- Total disclosed funding: $44M
- Latest round: Series B (Dec 16, 2025)
- Investors on record: 7

## About

Based in Shenzhen, China, and founded in 2022, Shen Zhen Oculgen BiomedicalTechnology Co., Ltd., dba Oculgen, operates as a biopharmaceutical technology company, focusing on innovative macromolecular ophthalmic therapies. The founder, Jiongguang Chen, is a PhD of University of Arizona and a postdoctoral fellow of University of California. The company has set up a R&D center in Zhuhai. It is recognized as a Suzhou Leading Entrepreneurial Talent Enterprise, and its core product OCUL10 has obtained clinical approval from FDA and CDE. In January 2025, Oculgen raised over CNY 100 million in series A funding led by new investor LongRiver Investments.

Oculgen specializes in the research and development of innovative ophthalmic therapies, particularly focusing on large-molecule drugs for treating serious eye diseases. The company addresses conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and glaucoma.

The company generates revenue by developing innovative dual-target, triple-effect antibodies that can be used to treat non-macular degeneration (nAMD), diabetic macular edema (DME) and geographic atrophy (GA).

The company will use the series A funding to accelerate the clinical progress of its multi-antibody pipeline in China and the United States. And its other pipelines under development are expected to submit INDs in China and the United States by the end of 2025.

## Funding rounds

- Series B, Dec 16, 2025, $30M — Qiming Venture Partners
- Series A, Jan 11, 2025, $14M — YuanBio Venture, Tsing Song Capital, Shanghai Junshi Biosciences Co., Ltd., BioTrack Capital, LongRiver Investments, Shenzhen Nanshan Huirong Investment

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Shanghai Junshi Biosciences Co., Ltd. — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- LongRiver Investments (https://capitalatlas.ai/funds/longriver-investments) — Series A
- Shenzhen Nanshan Huirong Investment — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B